Represents the additional term of extension of the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementAdditionalExtensionTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the initial period of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementAgreementTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the estimated utilization period after commercialization of the product, which is used to allocate fees to the deliverables in the contract.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementAllocationOfDeliverablesAssumptionsUtilizationPeriod
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the term of extension of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementExtensionTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the estimated term of licenses under the collaborative arrangements.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementLicensesEstimatedTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of potential payments that could be received under the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_CollaborativeArrangementMilestonePaymentsPotential
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include milestone and licensing fees revenue. Milestone revenue is consideration received upon achieving contractual goals. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets.

+ References

No definition available.

+ Details

Name:	imgn_LicenseAndMilestoneFees
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential payment to extend the term of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_PaymentsForCollaboratorsContractExtension
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the potential payments to expand the scope of the collaborative agreement.

+ References

No definition available.

+ Details

Name:	imgn_PaymentsForCollaboratorsContractScopeExpansion
Namespace Prefix:	imgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueInputsDiscountRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentAndCommercializationLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=imgn_TakedaOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_FutureTechnologicalImprovementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	imgn_MilestonePaymentsCategoryAxis=imgn_ResearchServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements - Takeda (Details)	1 Months Ended	3 Months Ended								12 Months Ended			16 Months Ended
Agreements - Takeda (Details)	Mar. 31, 2015 USD ($) item	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2016 USD ($) item	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2016 USD ($)	Dec. 31, 2006 USD ($)
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees		$ 76,000	$ 10,077,000	$ 10,692,000	$ 6,070,000	$ 5,086,000	$ 5,078,000	$ 41,417,000	$ 6,234,000	$ 26,915,000	$ 57,815,000	$ 39,455,000
Costs related to the research and development services		38,652,000	$ 36,094,000	$ 38,199,000	$ 35,132,000	$ 30,437,000	25,666,000	$ 27,647,000	$ 28,018,000	$ 148,077,000	111,768,000	106,958,000
Development and Commercialization License \| Development milestones
Collaborative Agreements disclosures
Potential milestone payments														$ 4,500,000
Takeda
Collaborative Agreements disclosures
Number of single-target licenses \| item										1
Costs related to the research and development services										$ 469,000	$ 113,000	$ 0
Takeda \| Right-to-test agreement
Collaborative Agreements disclosures
Number of single-target licenses \| item	2
Term of agreement	3 years
Term of extension of the agreement	1 year
Potential payments to extend the agreement term	$ 4,000,000
Potential payment to expand agreement scope	8,000,000
Payments received under collaboration agreement	20,000,000												$ 31,400,000
Potential milestone payments	$ 210,000,000						210,000,000
Additional term of extension of the agreement	2 years
Estimated utilization period after commercialization	10 years
Discount rate (as a percent)	13.00%
Estimated term of development and commercialization license	25 years
Remaining arrangement consideration to be recognized as license revenue		17,300,000								17,300,000			17,300,000
Takeda \| Right-to-test agreement \| Development milestones
Collaborative Agreements disclosures
Payments received under collaboration agreement													25,900,000
Potential milestone payments	$ 30,000,000						30,000,000
Takeda \| Right-to-test agreement \| Phase I clinical trial
Collaborative Agreements disclosures
Potential milestone payments		$ 5,000,000								5,000,000			5,000,000
Takeda \| Right-to-test agreement \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payments	85,000,000						85,000,000
Takeda \| Right-to-test agreement \| Sales milestones
Collaborative Agreements disclosures
Potential milestone payments	$ 95,000,000						$ 95,000,000
Takeda \| Right-to-test agreement \| Future Technological Improvements
Collaborative Agreements disclosures
Payments received under collaboration agreement													2,100,000
Takeda \| Right-to-test agreement \| Research Services
Collaborative Agreements disclosures
Payments received under collaboration agreement													$ 3,400,000
Takeda \| Development and Commercialization License
Collaborative Agreements disclosures
Amount of arrangement consideration included in license and milestone fees										$ 8,600,000